|Bid||8.90 x 900|
|Ask||8.96 x 1100|
|Day's Range||8.63 - 8.96|
|52 Week Range||7.10 - 19.90|
|Beta (5Y Monthly)||2.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.29|
The Compugen Ltd. ( NASDAQ:CGEN ) share price is down a rather concerning 39% in the last month. But over three years...
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the publication of a review article titled "Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis" reviewing the biology and therapeutic relevance of the DNAM-1 axis in cancer immunotherapy. The peer-reviewed article, published in Cancer Discovery, a journal of the American Association for Cancer Research, was co-authored by Drew Pardoll, M.D., Ph.D., Professor of Oncology, Johns Hopkins University and Chairman of Compugen's Scientific Advisory Board.
Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Oppenheimer 31st Annual Healthcare Conference (virtual), on Tuesday, March 16, 2021 at 10:40 AM ET.